AI Article Synopsis
- Advanced urothelial carcinoma has limited treatment options, particularly in later stages, with only a few drugs showing clinical effectiveness.
- The article highlights a young patient with serious cardiovascular issues who has already been treated with first- and second-line therapies and has liver metastases.
- Despite the generally poor prognosis, the patient responded well to a third-line treatment involving gemcitabine, making this case noteworthy for its unique therapy approach and disease progression.
Article Abstract
Therapeutic alternatives in advanced urothelial carcinoma are limited, especially in advanced lines, with only a few drugs having demonstrated relevant clinical benefit. This article discusses about a young patient with significant cardiovascular comorbidities, already treated with recommended first- and second-line drugs, and suffering from liver metastases. Despite the known poor prognosis of this disease and the few supporting data, given his peculiar clinical history, we opted to treat him with a third-line gemcitabine rechallenge with a notable response on his liver lesions. We present an intriguing case, both in terms of the therapeutic sequence and the disease course.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CAD.0000000000001387 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!